PCR Journal Club

Coronary microvascular dysfunction is increasingly recognised as a key determinant of outcomes beyond epicardial coronary disease. The FLOW-CMD registry provides new insights into its prevalence and prognostic impact in routine invasive practice.

Long-term evidence comparing PCI and CABG for unprotected left main coronary disease has been limited and sometimes conflicting. The 10-year results from the NOBLE trial now provide important clarity on all-cause mortality outcomes with both revascularisation strategies.

The RENOVATE-COMPLEX-PCI 5-year outcomes confirm the long-term durability of benefits seen with intracoronary imaging over angiography guided PCI in complex lesions.

The TICO1 and T-PASS2 trials evaluated abbreviated DAPT followed by ticagrelor monotherapy compared to DAPT in patients with ACS undergoing PCI. Both trials demonstrated the safety and efficacy of abbreviated DAPT however, the optimal timing of aspirin discontinuation remains uncertain. This post hoc analysis compares the...

The TUXEDO-2 trial sought to directly compare prasugrel versus ticagrelor in diabetic patients undergoing percutaneous coronary intervention (PCI), with the aim of clarifying whether the non-inferiority of ticagrelor could be established.

The present analysis compared major adverse cardiac events in patients with significant coronary stenosis (FFR ≤ 0.80 or visual stenosis ≥ 90 %) versus those with non-significant stenosis (FFR > 0.80).

In patients with severely calcified coronary lesions undergoing PCI, the BALI trial evaluated the benefit of the addition of intravascular lithotripsy to conventional lesion preparation on the composite endpoint of procedural failure and target vessel failure.

In the overall population (n = 2,114), there was a significant interaction between the effect of randomisation to OCT guidance vs angiography guidance in lesions with moderate/severe calcification (n = 1,082) vs no/mild calcification (n = 1,032) on the 2-year rate of TVF (Pinteraction = 0.01).

This analysis from the XIENCE Short DAPT programme compared the safety and efficacy of one-month versus three-month DAPT in high-bleeding risk patients with and without diabetes mellitus (DM) following PCI with everolimus eluting stents (EES).

This prespecified analysis of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME 3) trial examined the impact on cardiovascular outcomes of treatment by CABG versus FFR-guided PCI in patients with three vessel disease (3-VD), stratified by acute (NSTEMI) or chronic coronary syndrome (CCS) presentation.